Asco 2015 – Phase 1, first-in-human study of ARQ 087, an oral pan-Fibr
- This topic has 0 replies, 1 voice, and was last updated 9 years, 2 months ago by
.
Viewing 1 post (of 1 total)
-
Posts
-
Phase 1, first-in-human study of ARQ 087, an oral pan-Fibroblast Growth Factor Receptor (FGFR) inhibitor, in patients (pts) with advanced solid tumors.
http://abstracts.asco.org/156/AbstView_156_149025.html
Viewing 1 post (of 1 total)
- The forum ‘New Developments’ is closed to new topics and replies.